Table 31.
Occurrence of resistance (%) to selected antimicrobials in indicator Escherichia coli from fattening pigs, using harmonised ECOFFs, 28 EU MSs and 3 non‐MSs, 2017
| Country | N | GEN | CHL | AMP | CTX | CAZ | MEM | TGC | NAL | CIP | AZM | COL | SMX | TMP | TET |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 180 | 1.7 | 3.3 | 20 | 1.7 | 1.7 | 0 | 0 | 2.8 | 3.9 | 0.6 | 0 | 24.4 | 12.8 | 40.6 |
| Belgium | 176 | 1.1 | 26.1 | 51.1 | 7.4 | 7.4 | 0 | 0.6 | 4 | 9.1 | 1.7 | 0.6 | 47.7 | 44.9 | 46 |
| Bulgaria | 101 | 1 | 36.6 | 62.4 | 0 | 0 | 0 | 0 | 10.9 | 15.8 | 0 | 0 | 59.4 | 36.6 | 80.2 |
| Croatia | 86 | 2.3 | 11.6 | 30.2 | 0 | 0 | 0 | 0 | 11.6 | 15.1 | 0 | 0 | 40.7 | 23.3 | 48.8 |
| Cyprus | 57 | 8.8 | 54.4 | 63.2 | 0 | 0 | 0 | 0 | 8.8 | 21.1 | 12.3 | 0 | 82.5 | 70.2 | 87.7 |
| Czech Republic | 180 | 0.6 | 3.3 | 37.8 | 2.8 | 2.8 | 0 | 0 | 3.3 | 5 | 1.7 | 0 | 33.9 | 26.7 | 45.6 |
| Denmark | 172 | 2.3 | 5.8 | 35.5 | 0 | 0 | 0 | 0 | 0.6 | 0.6 | 1.2 | 0 | 34.9 | 30.2 | 37.2 |
| Estonia | 67 | 0 | 4.5 | 17.9 | 0 | 0 | 0 | 0 | 1.5 | 1.5 | 0 | 0 | 14.9 | 16.4 | 19.4 |
| Finland | 175 | 0 | 0.6 | 8.6 | 0 | 0 | 0 | 0 | 0.6 | 0 | 0 | 0 | 12 | 11.4 | 18.3 |
| France | 214 | 1.4 | 13.1 | 30.8 | 0 | 0 | 0 | 0 | 4.7 | 4.7 | 0.5 | 0 | 40.7 | 34.1 | 56.1 |
| Germany | 227 | 1.3 | 9.7 | 29.1 | 2.2 | 1.3 | 0 | 0 | 4.4 | 6.6 | 0.9 | 0.4 | 30 | 23.8 | 36.6 |
| Greece | 170 | 9.4 | 40.6 | 58.8 | 0.6 | 0.6 | 0 | 0 | 2.9 | 10 | 1.8 | 0.6 | 82.4 | 50 | 75.9 |
| Hungary | 170 | 1.8 | 17.1 | 44.7 | 1.2 | 1.2 | 0 | 0 | 5.3 | 7.6 | 2.4 | 1.8 | 31.8 | 25.9 | 66.5 |
| Ireland | 203 | 3.4 | 13.8 | 27.6 | 1.5 | 1.5 | 0 | 0 | 6.4 | 7.4 | 0 | 0 | 43.8 | 35.5 | 62.1 |
| Italy | 170 | 9.4 | 47.6 | 70.6 | 1.2 | 0.6 | 0 | 0 | 7.6 | 22.4 | 1.2 | 0.6 | 67.1 | 60 | 78.2 |
| Latvia | 149 | 2 | 4 | 26.8 | 0.7 | 0.7 | 0 | 0 | 3.4 | 9.4 | 0 | 0 | 22.1 | 13.4 | 31.5 |
| Lithuania | 99 | 4 | 8.1 | 28.3 | 0 | 0 | 0 | 0 | 4 | 10.1 | 0 | 1 | 26.3 | 21.2 | 45.5 |
| Luxembourg | 44 | 0 | 13.6 | 20.5 | 2.3 | 2.3 | 0 | 0 | 2.3 | 2.3 | 0 | 0 | 31.8 | 22.7 | 22.7 |
| Malta | 74 | 1.4 | 6.8 | 17.6 | 0 | 1.4 | 0 | 0 | 5.4 | 9.5 | 0 | 0 | 50 | 33.8 | 62.2 |
| Netherlands | 300 | 0.7 | 12.3 | 22 | 0.3 | 0.3 | 0 | 0 | 1.3 | 2 | 0.7 | 0 | 34.3 | 30.7 | 42.7 |
| Poland | 213 | 3.3 | 13.6 | 46.9 | 1.9 | 1.9 | 0 | 0 | 8 | 16 | 0 | 0 | 57.7 | 28.2 | 58.2 |
| Portugal | 142 | 2.8 | 44.4 | 59.9 | 3.5 | 3.5 | 0 | 0 | 12 | 21.1 | 16.2 | 2.1 | 68.3 | 56.3 | 89.4 |
| Romania | 170 | 5.9 | 38.8 | 61.2 | 2.4 | 2.4 | 0 | 0 | 18.2 | 34.7 | 4.1 | 1.2 | 55.9 | 35.3 | 60.6 |
| Slovakia | 85 | 0 | 12.9 | 49.4 | 0 | 0 | 0 | 0 | 2.4 | 3.5 | 0 | 0 | 35.3 | 28.2 | 50.6 |
| Slovenia | 85 | 0 | 16.5 | 34.1 | 3.5 | 2.4 | 0 | 0 | 14.1 | 20 | 0 | 0 | 28.2 | 14.1 | 25.9 |
| Spain | 170 | 4.7 | 35.3 | 77.1 | 2.9 | 2.9 | 0 | 0 | 19.4 | 44.7 | 1.8 | 0.6 | 63.5 | 60.6 | 88.8 |
| Sweden | 140 | 0 | 5.7 | 18.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20.7 | 15 | 9.3 |
| United Kingdom | 186 | 3.8 | 20.4 | 30.6 | 0 | 0 | 0 | 0 | 2.2 | 2.7 | 0 | 0 | 47.3 | 36.6 | 59.1 |
| Total (28 MSs) | 4205 | 2.7 | 18 | 38.5 | 1.4 | 1.3 | 0 | 0 | 5.7 | 10.6 | 1.5 | 0.3 | 42.4 | 32.2 | 52.1 |
| Iceland | 68 | 0 | 1.5 | 14.7 | 0 | 0 | 0 | 0 | 4.4 | 4.4 | 0 | 0 | 14.7 | 13.2 | 19.1 |
| Norway | 304 | 0.3 | 0.3 | 6.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.9 | 5.6 | 6.6 |
| Switzerland | 197 | 3 | 5.1 | 14.2 | 0 | 0 | 0 | 0 | 2 | 2.5 | 0.5 | 0 | 36 | 15.2 | 20.8 |
ECOFFs: epidemiological cut‐off values; MSs: Member States; N: number of isolates tested; GEN: gentamicin; CHL: chloramphenicol; AMP: ampicillin; CTX: cefotaxime; CAZ: Ceftazidime; MEM: meropenem; TGC: tigecycline; NAL: nalidixic acid; CIP: ciprofloxacin; AZM: azithromycin; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; TET: tetracycline.